Envudeucitinib

Envudeucitinib
Clinical data
Other names	FTP-637
Identifiers
	IUPAC name N-(4-{2-methoxy-3-[1-(trideuteriomethyl)-1H-1,2,4-triazol-3-yl]anilino}-5-(3,3,3-trideuteriopropanoyl)pyridin-2-yl)cyclopropanecarboxamide;
CAS Number	2417135-66-9;
PubChem CID	158715582;
IUPHAR/BPS	13205;
UNII	KD2MDJ4GAB;
KEGG	D13123;
Chemical and physical data
Formula	C22H18D6N6O3
Molar mass	426.506 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [2H]C([2H])([2H])CC(=O)c1cnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C([2H])([2H])[2H])n2)c1OC;
	InChI InChI=InChI=1S/C22H24N6O3/c1-4-18(29)15-11-23-19(26-22(30)13-8-9-13)10-17(15)25-16-7-5-6-14(20(16)31-3)21-24-12-28(2)27-21/h5-7,10-13H,4,8-9H2,1-3H3,(H2,23,25,26,30)/i1D3,2D3; Key:FKCATCQHVCOBCX-WFGJKAKNSA-N;

Envudeucitinib is an investigational new drug that is being evaluated for the treatment of psoriasis. It is a selective tyrosine kinase 2 (TYK2) inhibitor developed by Fronthera U.S. Pharmaceuticals LLC and now owned by Alumis, Inc. for the treatment of autoimmune diseases. Envudeucitinib targets the TYK2 signaling pathway, which plays a crucial role in regulating multiple pro-inflammatory cytokines such as IL-12, IL-23, and type I interferons.^[1]^[2]

References

↑ Deng L, Wan L, Liao T, Wang L, Wang J, Wu X, et al. (August 2023). "Recent progress on tyrosine kinase 2 JH2 inhibitors". International Immunopharmacology. 121 110434. doi:10.1016/j.intimp.2023.110434. PMID 37315371.
↑ Loo WJ, Turchin I, Prajapati VH, Gooderham MJ, Grewal P, Hong CH, et al. (2023). "Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway". Journal of Cutaneous Medicine and Surgery. 27 (1_suppl): 3S–24S. doi:10.1177/12034754221141680. PMID 36519621.

[pmid37315371-1] Deng L, Wan L, Liao T, Wang L, Wang J, Wu X, et al. (August 2023). "Recent progress on tyrosine kinase 2 JH2 inhibitors". International Immunopharmacology. 121 110434. doi:10.1016/j.intimp.2023.110434. PMID 37315371.

[pmid36519621-2] Loo WJ, Turchin I, Prajapati VH, Gooderham MJ, Grewal P, Hong CH, et al. (2023). "Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway". Journal of Cutaneous Medicine and Surgery. 27 (1_suppl): 3S–24S. doi:10.1177/12034754221141680. PMID 36519621.

[1]

[2]